Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy.

Published

Journal Article

A cohort of rhesus macaques with long-standing SIVmac251 infection (> or =5 mo) was treated with continuous antiretroviral therapy (ART). A group of eight macaques was vaccinated with or without simultaneous administration of low dose IL-2 with the highly attenuated poxvirus vector (NYVAC) vaccine candidate expressing the SIVmac structural gag-pol-env (gpe) genes and a novel chimeric fusion protein derived from the rev-tat-nef (rtn) regulatory genes. Control groups consisted of mock-vaccinated macaques or animals treated only with IL-2. Vaccination significantly expanded both virus-specific CD4(+) and CD8(+) T cell responses, and IL-2 further increased the vaccine-induced response to an immunodominant Gag epitope. Following antiretroviral treatment interruption, the viral set point was significantly lower in vaccinated than in control macaques for at least 4 consecutive mo, and viral containment was inversely correlated with vaccine-induced, virus-specific CD4(+) and CD8(+) T cell responses. These data provide the proof of concept that therapeutic vaccination before cessation of ART may be a feasible approach in the clinical management of HIV-1 infection.

Full Text

Duke Authors

Cited Authors

  • Tryniszewska, E; Nacsa, J; Lewis, MG; Silvera, P; Montefiori, D; Venzon, D; Hel, Z; Parks, RW; Moniuszko, M; Tartaglia, J; Smith, KA; Franchini, G

Published Date

  • November 1, 2002

Published In

Volume / Issue

  • 169 / 9

Start / End Page

  • 5347 - 5357

PubMed ID

  • 12391256

Pubmed Central ID

  • 12391256

International Standard Serial Number (ISSN)

  • 0022-1767

Digital Object Identifier (DOI)

  • 10.4049/jimmunol.169.9.5347

Language

  • eng

Conference Location

  • United States